| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
In order to clarify molecular mechanism of hormone-independent progression of prostate cancer, metastatic and/or castration-resistant prostate cancer cases were analyzed by clinical and/or molecular approaches. From these results, some molecular pathway of this process were investigated and new biomarkers were developed. Especially, we reported that OPG-RANK-RANKL pathway is found to be useful for predicting prognosis and Zoledronic acid, a bone modifying agent, has anti-tumor effect on metastatic prostate cancer cases. Also, wefound anti-tumor effect of dendritic cells induced by Sndai virus vector in rat prostate cancer model.
|
